Latest / The Buyout Show with Fexingo: Private Equity, Roll-Ups, and Business Acquisitions / How Private Equity Is Buying Up Eyeglass Lens Labs
Transcript
- Lucas: So there's this moment that happens, I think, a couple times a year for most people. You go to the eye doctor, you get a new prescription, and then you walk over to the little display wall and pick out frames. But what you probably don't think about is where the lenses actually come from. Luna: Right. You just assume the doctor's office sends it somewhere and a week later your glasses show up. But that 'somewhere' is increasingly owned by private equity. Lucas: Exactly. And it's a pretty fascinating roll-up story. The optical lens lab industry in the U.S. is estimated at roughly $5 billion in annual revenue. It's fragmented — the top ten players maybe control 40 percent of the market. And that's exactly the kind of landscape private equity firms love: lots of small regional operators with sticky customer relationships. Luna: Sticky because — once an optometrist picks a lab, they tend to stay, right? The lab has their prescription blanks, their coating preferences, their frame inventory data. Switching is a pain. Lucas: Exactly. High switching costs, recurring revenue — people need new glasses every year or two. And the labs themselves are capital intensive in a way that creates a moat. You need precision grinding equipment, coating chambers, edgers. It's not something a new entrant just stands up overnight. Lucas: So the roll-up play looks like this: a private equity firm buys a 'platform' — a mid-sized lab with good management and a solid regional footprint — and then uses it to acquire smaller labs, consolidate back-office functions, and negotiate better pricing with suppliers. Luna: Who's the big player doing this? I know EssilorLuxottica is the giant — they own LensCrafters, they own the frame brands, they own the lab network. But that's vertical integration. The PE angle is different. Lucas: Right. So one of the more active firms here is FFL Partners. They're a San Francisco-based private equity firm that focuses on healthcare and business services. In 2020, they acquired Walman Optical, which is based in Minneapolis. Walman was already a decent-sized lab network — about $300 million in revenue at the time. Lucas: Since then, FFL has used Walman as a platform to buy at least five other regional labs that I can find. In 2021 they bought Quality Optical of Tennessee. In 2022 they bought Central Optical in Texas. In 2023 they bought Crystal Clear Optical in the Midwest. And they've continued adding smaller shops. Luna: So what's the pitch to the independent optometrist? 'Keep sending your business here, nothing changes, except now we have better buying power'? Lucas: Basically, yeah. The lab keeps its local brand, the same sales rep comes to the doctor's office, the same phone number. But behind the scenes, Walman consolidates the purchasing of raw lens blanks, the AR coating materials, the edging equipment. They centralize accounting and HR. And they negotiate better contracts with the frame suppliers. Luna: And the optometrist doesn't really care, as long as the turnaround time stays fast and the quality doesn't drop. Lucas: Right. And here's the thing — independent optometrists have been squeezed by the big chains for years. They see EssilorLuxottica owning the whole chain from frame design to retail store. So a well-run independent lab network that keeps them competitive is actually appealing. Lucas: The question is whether the economics hold up for the PE firm. Lens labs typically operate on thin margins — maybe 10 to 12 percent EBITDA. You make money on volume and efficiency. So the roll-up thesis depends on actually achieving those back-office savings. Luna: And on the exit. Eventually FFL will want to sell Walman — either to another PE firm, or maybe to a strategic buyer like EssilorLuxottica itself. Lucas: Exactly. And I think that's the real endgame for a lot of these optical lab roll-ups. The strategic buyers are the big lens manufacturers — Essilor, Zeiss, Hoya — who might pay a premium to acquire a distribution network. Or it could be another PE firm looking for a larger platform. Luna: You know, this reminds me of something. We talk about PE buying up dental supply companies, vet clinics, car washes. But the optical lab story feels different because the consumer literally never sees the brand. You don't know if your lenses were ground by Walman or by a mom and pop lab in your town. Lucas: And that's part of the appeal for PE. There's no consumer brand risk. No one is picketing outside a lens lab. It's a pure B2B play where the customer — the optometrist — mainly cares about reliability. As long as the lab delivers, the consolidation is invisible. Lucas: The challenge is that the industry is not growing super fast. The U.S. eyeglass market grows maybe 2 to 3 percent a year, driven by population aging and more screen time. So the returns have to come from margin improvement and multiple expansion, not top-line growth. Luna: And that margin improvement is partly about technology. The big labs have invested in digital surfacing equipment that can produce free-form lenses — those high-index, aspheric designs that cost more. Independent labs that can't afford that equipment lose business. Lucas: That's a key point. A pe backed lab can justify the capital expenditure because it spreads the cost across a larger volume. A single-shop lab might not be able to afford a $500,000 digital surfacing machine. So the roll-up actually enables the network to offer higher-margin products. Lucas: So the thesis is pretty sound. But there are risks. One is that EssilorLuxottica continues to gain share in the retail channel, squeezing independent optometrists. If the independents shrink, the labs that serve them shrink too. Luna: Also, the labor market. Lens grinding is a skilled trade. Finding experienced technicians is hard. If you consolidate and then lose a key technician at an acquired lab, quality can slip fast. Lucas: Absolutely. And there's regulatory risk — though it's low. The FDA does regulate lenses as medical devices, but the bar isn't high. Still, a quality failure at one lab in a network could damage the whole platform's reputation with optometrists. Lucas: So far, the PE firms that have jumped into this space seem to be doing well. Besides FFL, there's also TSG Consumer Partners, which invested in a lab platform called VSP Optics — that's the lab arm of VSP, the big vision insurance company. And there've been some smaller platforms backed by family offices. Luna: I want to zoom out for a second. How many labs are we talking about total in the U.S.? Like, is this a market of thousands of small players? Lucas: It's hard to get an exact count, but industry sources suggest there are roughly 800 to 1,000 optical labs in the country. Most of them are very small — maybe $2 million to $10 million in revenue. The vast majority are owned by the founders, often opticians who started the business decades ago. Lucas: And many of those founders are nearing retirement age. That's another reason PE sees an opportunity — there's a succession gap. A lot of these owners don't have a family member who wants to take over. So they're open to selling, and PE can offer a clean exit. Luna: So the next five to ten years could see a wave of consolidation. Maybe the optical lab industry ends up looking like the dental lab industry, where a few large players now control most of the market. Lucas: Exactly. And I think consumers will barely notice — except maybe in pricing. One concern is that as consolidation reduces competition, prices for lenses could creep up. But because the buyer — the optometrist — still has choices, and because the big chains provide a price anchor, I don't expect massive jumps. Lucas: The more likely outcome is that the independent optometrist gets a better, more efficient lab partner, and the PE firms get a steady return. It's one of those quiet, behind the scenes consolidations that almost never makes headlines. Luna: Which is exactly the kind of story this show is for. Lucas: Exactly. So if you've ever wondered who actually makes the lenses in your glasses — well, there's a decent chance it's a company you've never heard of, backed by a private equity firm you've definitely never heard of. And that's the buyout business. Luna: Speaking of things you might not think about — Lucas, we get a lot of listeners who say these episodes help them think differently about the businesses they interact with every day. And we love that. Lucas: Yeah, and it's why we keep the show ad-free. But that's only possible because some listeners choose to support us. So if today's episode gave you a useful lens — pun intended — on the business behind your glasses, and you want to help us keep going, the link is buy me a coffee dot com slash fexingo. Luna: No pressure at all. Just if it's worth a coffee to you. And then we'll keep finding these hidden corners of the economy. Lucas: Alright, back to labs. One more interesting player I want to mention — there's a company called National Optronics, which makes the edging equipment used in labs. They've been bought and sold by PE a couple times. That tells you the whole ecosystem is being consolidated, not just the labs. Luna: Right. The suppliers get rolled up too. It's a pattern we see in every fragmented industry PE touches. Lucas: So for listeners who want to track this — watch for FFL Partners' exit from Walman. That'll be the signal on whether the optical lab thesis worked. If they sell at a good multiple, expect a lot more firms to start calling up lab owners. Luna: And if you're an optometrist listening — maybe start thinking about what your lab's ownership structure is. It might change sooner than you think. Lucas: Alright, that's it for this episode of The Buyout Show. We'll be back next time with another industry you never knew private equity was buying up.